Daré Bioscience, Inc. (DARE)
| Market Cap | 13.28M -51.2% |
| Revenue (ttm) | 1.37M +10,429.4% |
| Net Income | -10.99M |
| EPS | -0.78 |
| Shares Out | 19.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,854 |
| Open | 0.7390 |
| Previous Close | 0.6996 |
| Day's Range | 0.6769 - 0.7390 |
| 52-Week Range | 0.6250 - 3.7800 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 6.33 (+838.22%) |
| Est. Earnings | Nov 16, 2026 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto... [Read more]
Financial Performance
In 2025, Daré Bioscience's revenue was $1.03 million, an increase of 10429.36% compared to the previous year's $9,784. Losses were -$13.40 million, 230.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price target is $6.33, which is an increase of 838.22% from the latest price.
News
Dare Bioscience receives additional $1.5M funding installment for DARE-LARC1
Dare Bioscience (DARE) announced receipt of an additional $1.5M funding installment under its multi-year grant agreement in support of development of DARE-LARC1, an investigational long-acting reversi...
Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development
Daré Bioscience Addresses New National Focus on Women's Health in Virtual Investor “What This Means” Discussion
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience's growing commercial portfolio and clinical pipeline position the ...
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on October 27, 2026, providing details for shareholder voting and corporate governance matters.
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program
Dare Bioscience initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Dare Bioscience (DARE) with a Buy rating and $2 price target
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women's health needs, including for women affected by breast c...
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities
New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic...
Dare Bioscience to present Sildenafil Cream data at SMSNA meeting
Dare Bioscience (DARE) announced that clinical data from a Phase 1 study that evaluated the company’s proprietary Sildenafil Cream, 3.6% investigational product will be presented at the Annual Fall Sc...
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Dare Bioscience announces issuance of patent for DARE-HPV program
Dare Bioscience (DARE) announced the issuance of U.S. Patent No. 12,678,439, titled “Lopinavir and Ritonavir for the Treatment of Cervix Disorders,” which covers pharmaceutical compositions formulated...
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on September 23, 2026, providing details for shareholder voting and corporate governance matters.
Dare Bioscience publishes results from Sildenafil Cream study
Dare Bioscience (DARE) announced the publication of results from a Phase 1 clinical study evaluating the safety and systemic pharmacokinetics of topical Sildenafil Cream, 3.6% in healthy adult men in…
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%
Daré Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two revenue-generating products are launching in 2026, supported by a scalable digital health platform and strong provider relationships. Late-stage clinical programs for contraception and HPV are set for key data readouts next year, with a robust pipeline fueled by non-dilutive funding.
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
View the video webcast here
Daré Bioscience Slides: Corporate presentation
Daré Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2
Dare Bioscience (DARE) announced that it received a new notice of award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, of the National…
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Video webcast now available here
Daré Bioscience Transcript: Investor update
A pivotal period is underway with new product launches, including Flora Sync LF5 and DARE to PLAY, and major clinical milestones expected next year for Ovaprene and DARE-HPV. The strategy leverages grant funding, digital engagement, and provider relationships for capital-efficient growth.
Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necess...
Daré Bioscience Registration statement: Registration filing
Daré Bioscience filed a registration statement on August 26, 2026, providing details about a securities offering with the SEC.
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove...